Sector News

Bayer sees IPO cash as war chest for new consumer deals

November 24, 2014
Life sciences
Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company’s CEO says.
 
Bayer is spinning off plastics in a move away from its chemical roots, preferring to focus on its fast-growing pharma unit and its assets in an expanding consumer health space. The proceeds will help Bayer march toward its goal of becoming the largest OTC player in the world, chief exec Marijn Dekkers told the Financial Times, tabbing the consumer health market as an “obvious consolidation play.”
 
To see that, one just needs to look at the array of different suppliers to the shelves of pharmacy giants like Boots in the U.K., he points out. “That means that nobody has really optimized their relationship with Boots yet,” he told the paper.
 
And Bayer wants to be at the front of the pack. It’s shown as much so far this year, grabbing China’s Dihon Pharmaceuticals before shelling out $14.2 billion for Merck’s consumer unit.
 
“We believe that critical mass is important,” he told the Times. “You need to be a large player there. If you don’t participate in consolidation you fall behind, and that is competitively dangerous.”
 
Other drugmakers have received that memo, too. Fellow pharma giants GlaxoSmithKline and Novartis this April agreed to team up on a consumer health joint venture, which will take the top spot in the OTC market after the deal closes next year. And then there’s Perrigo, which will vault into the top 5 after inking a $4.5 billion deal for Belgium’s Omega Pharma last month, the FT notes.
 
As Bayer looks to snap up future OTC targets, it might have a slew of additional competitors to fend off, too. Sanofi, for one, has actively grown its consumer health business since buying out Tennessee’s Chattem, and it was rumored to be a potential bidder for Omega–along with Bayer itself. Reckitt Benckiser, which entered a two-horse race for the Merck unit this year before ceding it to the German company, plans to spin off its underperforming pharma unit to double down on OTC, too.
 
By Carly Helfand
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]